Elacridar

Drug Profile

Elacridar

Alternative Names: 120918; GF 120918; GG 918; GW 120918

Latest Information Update: 15 May 2007

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Acridines; Chemosensitisers; Tetrahydroisoquinolines
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 15 Mar 2006 This compound is still in active development for Cancer
  • 03 Dec 2003 This compound is still in active development for Cancer
  • 23 Oct 2003 Phase-I clinical trials in Cancer in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top